Copyright
©The Author(s) 2023.
World J Gastrointest Pharmacol Ther. Dec 12, 2023; 14(5): 39-49
Published online Dec 12, 2023. doi: 10.4292/wjgpt.v14.i5.39
Published online Dec 12, 2023. doi: 10.4292/wjgpt.v14.i5.39
Dietary modifications | n = 1001 | Concomitant supplements | n = 1001 | Concomitant medication | n = 1001 |
FODMAP | 50 (50%) | Prebiotics | 60 (60%) | Rifaximin | 35 (35%) |
Gluten-free | 51 (51%) | Probiotics | 76 (76%) | Eluxadoline | 22 (22%) |
Keto | 36 (36%) | Peppermint oil | 45 (45%) | Antispasmodics | 12 (12%) |
Elimination | 50 (50%) | Fiber | 86 (86%) | SSRIs | 8 (8%) |
High fiber | 53 (53%) | Ginger | 52 (52%) | Tricyclic antidepressant | 8 (8%) |
Low fiber | 43 (43%) | Magnesium | 55 (55%) | Anticholinergic medication | 14 (14%) |
- | - | Vitamin D | 57 (57%) | Antidiarrheal medications | 32 (32%) |
- | - | - | - | Bile acid sequestrants | 9 (9%) |
- | - | - | - | Ondansetron | 8 (8%) |
- Citation: Niles SE, Blazy P, Cheuvront SN, Kenefick RW, Vidyasagar S, Smith AB, Fawkes N, Denman W. Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study. World J Gastrointest Pharmacol Ther 2023; 14(5): 39-49
- URL: https://www.wjgnet.com/2150-5349/full/v14/i5/39.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v14.i5.39